吸烟哮喘患者短期阿伐他汀治疗的疗效---随机对照试验
2011/06/17
摘要
背景：他汀类药物的免疫调节特性可能会有助于吸烟者的哮喘治疗。我们认为，短期阿伐他丁治疗能改善吸烟哮喘患者的肺功能或哮喘控制。
方法：71名吸烟的轻度至中度哮喘患者入选本研究，双盲法将其随机分为两个平行组，一组采用阿伐他丁（40 mg/d）治疗，一组采用安慰剂治疗。治疗4周后，两组患者均采用倍氯米松（400 μg/d）吸入治疗4周。主要结果为治疗4周后的晨间呼气峰值流量。次要结果为哮喘控制和气道炎症指标。
结果：治疗4周后，与安慰剂组相比，阿伐他丁组在晨间呼气峰值流量上无显著差异[-10.67 L/min, 95% CI -38.70~17.37, p=0.449]，但在哮喘生活质量评分方面显著改善[0.52, 95% CI 0.17 to 0.87 p=0.005]。治疗8周后，阿伐他丁联合倍氯米松组与单独倍氯米松组相比，在疗效上无显著差异。
结论：对于吸烟的轻度至中度哮喘患者，采用阿伐他丁短期治疗并不能改善肺功能，但能改善哮喘相关生活质量。临床试验注册号为：NCT00463827。
（林江涛 审校）
BMC Pulm Med. 2011 Apr 7;11(1):16. [Epub ahead of print]
Effects of short-term treatment with atorvastatin in smokers with asthma - a randomized controlled trial.
Braganza G, Chaudhuri R, McSharry C, Weir CJ, Donnelly I, Jolly L, Lafferty J, Lloyd SM, Spears M, Mair F, Thomson NC.
Abstract
BACKGROUND: The immune modulating properties of statins may benefit smokers with asthma. We tested the hypothesis that short-term treatment with atorvastatin improves lung function or indices of asthma control in smokers with asthma.
METHODS: Seventy one smokers with mild to moderate asthma were recruited to a randomized double-blind parallel group trial comparing treatment with atorvastatin (40 mg per day) versus placebo for 4 weeks. After 4 weeks treatment inhaled beclometasone (400 ug per day) was added to both treatment arms for a further 4 weeks. The primary outcome was morning peak expiratory flow after 4 weeks treatment. Secondary outcome measures included indices of asthma control and airway inflammation.
RESULTS: At 4 weeks, there was no improvement in the atorvastatin group compared to the placebo group in morning peak expiratory flow [-10.67 L/min, 95% CI -38.70 to 17.37, p=0.449], but there was an improvement with atorvastatin in asthma quality of life score [0.52, 95% CI 0.17 to 0.87 p=0.005]. There was no significant improvement with atorvastatin and inhaled beclometasone compared to inhaled beclometasone alone in outcome measures at 8 weeks.
CONCLUSIONS: Short-term treatment with atorvastatin does not alter lung function but may improve asthma quality of life in smokers with mild to moderate asthma. Clinicaltrials.gov identifier: NCT00463827.
BMC Pulm Med. 2011 Apr 7;11(1):16. [Epub ahead of print]
背景：他汀类药物的免疫调节特性可能会有助于吸烟者的哮喘治疗。我们认为，短期阿伐他丁治疗能改善吸烟哮喘患者的肺功能或哮喘控制。
方法：71名吸烟的轻度至中度哮喘患者入选本研究，双盲法将其随机分为两个平行组，一组采用阿伐他丁（40 mg/d）治疗，一组采用安慰剂治疗。治疗4周后，两组患者均采用倍氯米松（400 μg/d）吸入治疗4周。主要结果为治疗4周后的晨间呼气峰值流量。次要结果为哮喘控制和气道炎症指标。
结果：治疗4周后，与安慰剂组相比，阿伐他丁组在晨间呼气峰值流量上无显著差异[-10.67 L/min, 95% CI -38.70~17.37, p=0.449]，但在哮喘生活质量评分方面显著改善[0.52, 95% CI 0.17 to 0.87 p=0.005]。治疗8周后，阿伐他丁联合倍氯米松组与单独倍氯米松组相比，在疗效上无显著差异。
结论：对于吸烟的轻度至中度哮喘患者，采用阿伐他丁短期治疗并不能改善肺功能，但能改善哮喘相关生活质量。临床试验注册号为：NCT00463827。
（林江涛 审校）
BMC Pulm Med. 2011 Apr 7;11(1):16. [Epub ahead of print]
Effects of short-term treatment with atorvastatin in smokers with asthma - a randomized controlled trial.
Braganza G, Chaudhuri R, McSharry C, Weir CJ, Donnelly I, Jolly L, Lafferty J, Lloyd SM, Spears M, Mair F, Thomson NC.
Abstract
BACKGROUND: The immune modulating properties of statins may benefit smokers with asthma. We tested the hypothesis that short-term treatment with atorvastatin improves lung function or indices of asthma control in smokers with asthma.
METHODS: Seventy one smokers with mild to moderate asthma were recruited to a randomized double-blind parallel group trial comparing treatment with atorvastatin (40 mg per day) versus placebo for 4 weeks. After 4 weeks treatment inhaled beclometasone (400 ug per day) was added to both treatment arms for a further 4 weeks. The primary outcome was morning peak expiratory flow after 4 weeks treatment. Secondary outcome measures included indices of asthma control and airway inflammation.
RESULTS: At 4 weeks, there was no improvement in the atorvastatin group compared to the placebo group in morning peak expiratory flow [-10.67 L/min, 95% CI -38.70 to 17.37, p=0.449], but there was an improvement with atorvastatin in asthma quality of life score [0.52, 95% CI 0.17 to 0.87 p=0.005]. There was no significant improvement with atorvastatin and inhaled beclometasone compared to inhaled beclometasone alone in outcome measures at 8 weeks.
CONCLUSIONS: Short-term treatment with atorvastatin does not alter lung function but may improve asthma quality of life in smokers with mild to moderate asthma. Clinicaltrials.gov identifier: NCT00463827.
BMC Pulm Med. 2011 Apr 7;11(1):16. [Epub ahead of print]
